NT5E and neoplasm: In conclusion, the present biodistribution and SPECT/CT studies in tumor-bearing mice suggest that the radiolabeled anti-CD73 human monoclonal antibody 067-213 has the potential to noninvasively determine CD73 expression levels in cancer patients.